Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | HDAC4 | P56524 | 15/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 13/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 8/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.48 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.48 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.48 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.48 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.48 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.48 |
| ▸ | KLHL20 | Q9Y2M5 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14952755 | 0.87 | SMN1; SMN2 (0.51) | SMN1; SMN2HDAC4HDAC1HDAC6HDAC3 | |
| SCHEMBL14952768 | 0.85 | HDAC4 (0.56) | SMN1; SMN2HDAC4HDAC1HDAC6HDAC3 | |
| SCHEMBL14952791 | 0.83 | SMN1; SMN2 (0.56) | SMN1; SMN2HDAC4HDAC1HDAC6HDAC3 | |
| SCHEMBL30281500 | 0.83 | SMN1; SMN2 (0.56) | SMN1; SMN2HDAC4HDAC1HDAC6HDAC3 | |
| SCHEMBL14952813 | 0.81 | SMN1; SMN2 (0.57) | SMN1; SMN2HDAC4HDAC1HDAC6HDAC3 | |
| SCHEMBL4405235 | 0.81 | SMN1; SMN2 (0.57) | SMN1; SMN2HDAC4HDAC1HDAC6HDAC3 | |
| SCHEMBL4402054 | 0.81 | SMN1; SMN2 (0.57) | SMN1; SMN2HDAC4HDAC1HDAC6HDAC3 | |
| SCHEMBL12228285 | 0.81 | SMN1; SMN2 (0.57) | SMN1; SMN2HDAC4HDAC1HDAC6HDAC3 | |
| SCHEMBL14952812 | 0.78 | HDAC4 (0.55) | SMN1; SMN2HDAC4HDAC1HDAC6HDAC3 | |
| SCHEMBL14952806 | 0.78 | SMN1; SMN2 (0.58) | SMN1; SMN2HDAC4HDAC1HDAC6HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4594325-A1 | PEG-MODIFIED CYCLIC DIPEPTIDES | Novmetapharma Co., Ltd. (KR) | 2025-08-06 | — | — | EP | claimed |
| US-20240140955-A1 | PEG-MODIFIED CYCLIC DIPEPTIDES | NOVMETAPHARMA CO., LTD. (KR) | 2024-05-02 | — | — | US | claimed |
| WO-2024069524-A1 | PEG-MODIFIED CYCLIC DIPEPTIDES | NOVMETAPHARMA CO., LTD. (KR) | 2024-04-04 | — | — | WO | claimed |
| EP-4594325-A1 | PEG-MODIFIED CYCLIC DIPEPTIDES | Novmetapharma Co., Ltd. (KR) | 2025-08-06 | — | — | EP | disclosed |
| US-20240140955-A1 | PEG-MODIFIED CYCLIC DIPEPTIDES | NOVMETAPHARMA CO., LTD. (KR) | 2024-05-02 | — | — | US | disclosed |
| WO-2024069524-A1 | PEG-MODIFIED CYCLIC DIPEPTIDES | NOVMETAPHARMA CO., LTD. (KR) | 2024-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240140955-A1 | PEG-MODIFIED CYCLIC DIPEPTIDES | LNPEP, ANPEP, DNPEP | SMN1; SMN2 4537/4885HDAC4 1691/4885HDAC1 506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.